Here, we summarize our own ROP treatment data between 2010 and 2018 of cases diagnosed with type 1 ROP or A-ROP, treated with anti-VEGF agents (including bevacizumab, ranibizumab, conbercept) or laser photocoagulation primarily at our eye center, and followed for at least 6 months. The gene discussed is VEGFA; the disease is retinopathy of prematurity.